Surgical Treatment of Hepatocellular Carcinoma

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".

Deadline for manuscript submissions: 31 January 2025 | Viewed by 431

Special Issue Editor


E-Mail Website
Guest Editor
Department of General Surgery and Chang Gung Transplantation Institute, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan 33302, Taiwan
Interests: liver surgery; liver transplantation; tumor immunology; dendritic cell immunotherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Hepatocellular carcinoma (HCC) is the most common primary malignancy in the liver. Surgical treatment remains the most important treatment for HCC. Traditionally, surgical treatment is limited to treating the early stages of HCC. However, most cases of HCC are found at the late stages. Whether surgical treatment has a role in the treatment of HCC beyond the early stage is an important issue. 

The tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor (ICI) are applied to treat advanced HCC with promising effects. Some instances of advanced HCC can be downstaged by TKI/ICI. Thus, the treatment for HCC has changed in the ICI era. Along with the progression of medical treatments, the aspects of surgical treatment for HCC have also changed, and challenges have been raised. The role of surgical treatment in the ICI era has to be renewed. 

Surgical treatment is a curative treatment for HCC. However, surgical treatment is frequently criticized for the high rate of tumor recurrence. Neoadjuvant or adjuvant treatments to supplement surgical treatment may help to improve the outcomes of surgical treatment, but effective adjuvant treatments are still lacking. 

This Special Issue entitled “Surgical Treatment of Hepatocellular Carcinoma” focuses on the innovation of surgical treatments. We are pleased to invite you to submit manuscripts to this Special Issue. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: surgical techniques, surgical indications, surgical outcomes, clinical trials, liver transplantation, adjuvant therapy, basic research, etc.

We look forward to receiving your contributions. 

Prof. Dr. Wei-Chen Lee
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • surgical techniques
  • surgical indications
  • surgical outcomes
  • clinical trials
  • liver transplantation
  • adjuvant therapy
  • basic research

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

9 pages, 570 KiB  
Article
Conversion Therapy to Transplant or Surgical Resection in Patients with Unresectable Hepatocellular Carcinoma Treated with Boosted Dose of Yttrium-90 Radiation Segmentectomy
by Sam Y. Son, Ruben Geevarghese, Brett Marinelli, Ken Zhao, Anne Covey, Aaron Maxwell, Alice C. Wei, William Jarnagin, Michael D’Angelica and Hooman Yarmohammadi
Cancers 2024, 16(17), 3024; https://doi.org/10.3390/cancers16173024 - 30 Aug 2024
Viewed by 290
Abstract
Background/Objectives: The aim of this study was to assess the efficacy of boosted dose yttrium-90 radioembolization (TARE) as a modality for conversion therapy to transplant or surgical resection in patients with unresectable hepatocellular carcinoma (HCC). Methods: In this single-center retrospective study, all patients [...] Read more.
Background/Objectives: The aim of this study was to assess the efficacy of boosted dose yttrium-90 radioembolization (TARE) as a modality for conversion therapy to transplant or surgical resection in patients with unresectable hepatocellular carcinoma (HCC). Methods: In this single-center retrospective study, all patients with a diagnosis of HCC who were treated with boosted dose TARE (>190 Gy) between January 2013 and December 2023 were reviewed. Treatment response and decrease in tumor size were assessed with the RECIST v1.1 and mRECIST criteria. Milan and University of California, San Francisco (UCSF), criteria were used to determine transplant eligibility, and Barcelona Clinic Liver Cancer (BCLC) surgical resection recommendations were used to evaluate tumor resectability. Results: Thirty-eight patients with primary HCC who were treated with boosted dose TARE were retrospectively analyzed. The majority of the patients were Child–Pugh A (n = 35; 92.1%), BCLC C (n = 17; 44.7%), and ECOG performance status 0 (n = 25; 65.8%). The mean sum of the target lesions was 6.0 cm (standard deviation; SD = 4.0). The objective response rate (ORR) was 31.6% by RECIST and 84.2% by mRECIST. The disease control rate (DCR) was 94.7% by both RECIST and mRECIST. Among patients outside of Milan or UCSF, 13/25 (52.0%, Milan) and 9/19 (47.4%, UCSF) patients were successfully converted to within transplant criteria. Of patients who were initially unresectable, conversion was successful in 7/26 (26.9%) patients. Conclusions: This study provides further real-world data demonstrating that boosted-dose TARE is an effective modality for conversion of patients with unresectable HCC to transplant or resection. Full article
(This article belongs to the Special Issue Surgical Treatment of Hepatocellular Carcinoma)
Show Figures

Figure 1

Back to TopTop